Final-Program-ATS-2023-AP.vp

336

WEDNESDAY • MAY 24

12:48 Utility of the 52-Gene Risk Score to Identify Patients With Idiopathic Pulmonary Fibrosis at Greater Risk of Mortality in the Era of Antifibrotic Therapy/ J. Soellner, Biberach, Germany 1:00 Validation of A 25-Gene Blood Transcriptomic Signature Predictive of Forced Vital Capacity Decline in Patients With Idiopathic Pulmonary Fibrosis/ C. Bonham, Charlottesville, VA 1:12 Increasing Honeycombing and Traction Bronchiectasis on Computed Tomography Are Independent Predictors of Survival Across All Interstitial Lung Disease Subtypes/ D. Marinescu, Vancouver, Canada 1:24 AI-based Model for the Automatized Quantification and Prognosis of IPF Patients/ J. Guiot, Liege, Belgium 1:36 Imaging Signature Idiopathic Pulmonary Fibrosis (IS-IPF): An Analytic Validation Study of Two CT Image-based Biomarkers in an Independent Cohort for Predicting Disease Progression in Non- IPF Interstitial Lung Diseases/ G.J. Kim, Los Angeles, CA 1:48 Chest Computed Tomography Machine Learning Classifier for Idiopathic Pulmonary Fibrosis Predicts Mortality in Interstitial Lung Diseases/ O. Moran Mendoza, Kingston, Canada

12:00 Welcome and Introduction of Speakers V. Kundel, MD, New York, NY 12:05 Sleep Apnea, Biomarkers of Vascular Injury and Inflammation S. Jelic, MD, New York, NY 12:20 Role of Epigenetic Regulation in Sleep Apnea R. Cortese, PhD, Columbia, MO 12:35 Epidemiological and Genetic Associations Between Sleep-Disordered Breathing and Inflammatory Traits B.E. Cade, PhD, Boston, MA 12:50 Investigating the Impact of Sleep Health on

HIV-Associated Inflammation P.V. Borker, MD, Pittsburgh, PA 1:05 OSA and Chronic Lung Disease M. Teodorescu, MD, MS, Madison, WI 1:20 Question and Answer/Panel Discussion

CLINICAL • TRANSLATIONAL MINI SYMPOSIUM

D91

LOOKING FOR THE CRYSTAL BALL: BIOMARKERS TO PREDICT DISEASE PROGRESSION AND MORTALITY IN ILD

CLINICAL MINI SYMPOSIUM

12:00 p.m. - 2:00 p.m.

Walter E. Washington Convention Center Ballroom A (Level 3)

Chairing: D.A. Lynch, MB BCh, Denver, CO

D92

NOVEL IMAGING AND PHYSIOLOGIC MEASURES IN COPD

A.E. Tzouvelekis, MD, PhD, Patras, Greece M. Kang, MD, Atlanta, GA

12:00 p.m. - 2:00 p.m.

Walter E. Washington Convention Center Room 147 A-B (Street Level)

Featured Speaker: 12:00 Biomarkers for Pulmonary Fibrosis; What Do We Know and What Do We Need to Know?/ T.M. Maher, Los Angeles, CA Oral Presentations: 12:12 In the Serial Assessment of Patients With Idiopathic Pulmonary Fibrosis, the Automated E-ILD CT Algorithm Outperforms Lung Function; a Validation Study/ P.M. George, London, United Kingdom 12:24 Proteomic Determinants of Idiopathic Pulmonary Fibrosis Survival/ J. Oldham, Ann Arbor, MI 12:36 Association of Circulating Metabolites With Disease Severity and Mortality in Patients With Idiopathic Pulmonary Fibrosis: Data From the IPF-PRO Registry/ R.S. Summer, Philadelphia, PA

Chairing: C.B. Cooper, MD, Los Angeles, CA B.M. Smith, MD, MS, Montreal, Canada T. Lapperre, MD, Edegem, Belgium Oral Presentations: 12:00 Computed Tomography Total Vessel Count in Chronic Obstructive Pulmonary Disease: Association With Pulmonary Function/ G.V. Singh, Toronto, Canada 12:12 Silent Airway Mucus Plugs in COPD and Association With Disease Severity and Outcomes/ S.K. Mettler, Boston, MA 12:24 Texture-based Computed Tomography Radiomics With Machine Learning Improves Predicting Chronic Obstructive Pulmonary Disease Outcomes/ K. Makimoto, Toronto, Canada 12:36 Topologic Parametric Response Mapping Identifies Emphysema Progression Subtypes in COPDGene/ J.M. Wang, Ann Arbor, MI

ATS 2023 • Washington, DC